Back to results
US 2022/0031811 A1Published application
Insulin glargine/lixisenatide fixed ratio formulation
AssigneeSanofi-Aventis Deutschland GmbH
InventorsElisabeth Souhami, Louise Silvestre
Life of this patent
Estimating the term…
Abstract
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Claims8
A pharmaceutical composition comprising
- (a) lixisenatide or a pharmaceutically acceptable salt thereof, and
- (b) insulin glargine or a pharmaceutically acceptable salt thereof,
- wherein the compound (b) and compound (a) are present in a ratio of about 1.6 to about 2.4 U of compound (b) per μg of compound (a).
Dependencies are inferred from the claim text.